ANGO Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -6.12% compared to AngioDynamics's net margin of --. AngioDynamics's return on equity of -20.83% beat Perspective Therapeutics's return on equity of --.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 68.82%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 494.75%. Given that Perspective Therapeutics has higher upside potential than AngioDynamics, analysts believe Perspective Therapeutics is more attractive than AngioDynamics.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are larger than Perspective Therapeutics quarterly revenues of --. AngioDynamics's net income of -$4.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, AngioDynamics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.33x versus 15.67x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -6.12% compared to AngioDynamics's net margin of -45.89%. AngioDynamics's return on equity of -20.83% beat Masimo's return on equity of -39.91%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 68.82%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 18.55%. Given that AngioDynamics has higher upside potential than Masimo, analysts believe AngioDynamics is more attractive than Masimo.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Masimo quarterly revenues of $372M. AngioDynamics's net income of -$4.4M is higher than Masimo's net income of -$170.7M. Notably, AngioDynamics's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.33x versus 4.22x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of -6.12% compared to AngioDynamics's net margin of 8.48%. AngioDynamics's return on equity of -20.83% beat Merit Medical Systems's return on equity of 9.19%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 68.82%. On the other hand Merit Medical Systems has an analysts' consensus of $107.00 which suggests that it could grow by 11.35%. Given that AngioDynamics has higher upside potential than Merit Medical Systems, analysts believe AngioDynamics is more attractive than Merit Medical Systems.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.439%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are smaller than Merit Medical Systems quarterly revenues of $355.4M. AngioDynamics's net income of -$4.4M is lower than Merit Medical Systems's net income of $30.1M. Notably, AngioDynamics's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 47.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.33x versus 4.16x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -6.12% compared to AngioDynamics's net margin of -10.04%. AngioDynamics's return on equity of -20.83% beat Xtant Medical Holdings's return on equity of -35.34%.

AngioDynamics has a consensus price target of $15.67, signalling upside risk potential of 68.82%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 225.89%. Given that Xtant Medical Holdings has higher upside potential than AngioDynamics, analysts believe Xtant Medical Holdings is more attractive than AngioDynamics.

AngioDynamics has a beta of 0.582, which suggesting that the stock is 41.778% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $72M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. AngioDynamics's net income of -$4.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, AngioDynamics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.33x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.